EUVIMEDEUVIMED entdecken
Crossref

Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?

William Lewis, Amy Forrestel, Emily Baumrin

Cutis · 2023

DOI: 10.12788/cutis.0681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cutis, 2023. Verfasst von William Lewis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Exanthema, Drug Eruptions. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous adverse events (AEs), including papulopustular eruptions, paronychia, acral fissures, xerosis, alopecia, and trichomegaly. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a cutaneous reaction that has been uncommonly reported in association with EGFR inhibitors, though the optimal management strategy for this condition is unknown. We present 2 cases of SDRIFE secondary to EGFR inhibitor therapy in which the EGFR inhibitor was successfully continued while topical therapy was administered for effective control of symptoms. We also review the literature on EGFR inhibitor-related SDRIFE to assess the range of approaches to treating this condition. Our analysis suggests that the dermatologist is critical in diagnosing and treating this cutaneous AE, which may be supported with skin-directed therapy and may not require discontinuation of cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExanthemaDrug EruptionsHumansSkinAdministration, CutaneousErbB Receptors

Substanzen

ErbB Receptors

Autor:innen und Institutionen

  • Department of Dermatology, University of Pennsylvania, Philadelphia.

Zitieren

APA

Lewis, W., Forrestel, A., & Baumrin, E. (2023). Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?. Cutis. https://doi.org/10.12788/cutis.0681

Vancouver

Lewis W, Forrestel A, Baumrin E. Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?. Cutis. 2023. doi:10.12788/cutis.0681

BibTeX
@article{Lewis2023,
  author = {Lewis, William and Forrestel, Amy and Baumrin, Emily},
  title = {Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?},
  journal = {Cutis},
  year = {2023},
  doi = {10.12788/cutis.0681}
}
Kostenlos starten →